Cutia Therapeutics

02487

Company Profile

  • Business description

    Cutia Therapeutics is a dermatology focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.

  • Contact

    436 Heng Feng Road
    20th Floor, Huanzhi Building
    Jingan District
    Shanghai200070
    CHN

    T: +86 2152982688

    https://www.cutiatx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    298

Stocks News & Analysis

stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks

Our only 5-star wide moat ASX share

A difficult year but better times ahead.
stocks

Is this still an ASX share to own forever?

Find out how this defensive player has fared after earnings.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,140.5011.000.12%
CAC 407,674.7824.14-0.31%
DAX 4023,596.98173.35-0.73%
Dow JONES (US)45,400.86220.43-0.48%
FTSE 1009,208.218.66-0.09%
HKSE25,417.98359.471.43%
NASDAQ21,700.397.30-0.03%
Nikkei 22543,018.75438.481.03%
NZX 50 Index13,223.5390.330.69%
S&P 5006,481.5020.58-0.32%
S&P/ASX 2008,871.208.600.10%
SSE Composite Index3,812.5146.641.24%

Market Movers